Testing the Addition of an IDH1 Inhibitor, Olutasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH1 Mutation (A MyeloMATCH Treatment Trial)

Launched by NATIONAL CANCER INSTITUTE (NCI) ·

Keywords

ClinConnect Summary

This clinical trial is testing whether adding a new medicine called olutasidenib to the usual treatment can help people with a type of blood disorder called higher-risk myelodysplastic syndrome (MDS) that has a specific gene change called an IDH1 mutation. The usual treatment includes two medicines, cedazuridine and decitabine, which work together to help the bone marrow make healthy blood cells and reduce abnormal ones. Sometimes, another medicine called venetoclax is also used. Olutasidenib targets the abnormal protein made by the mutated gene and may help stop the cancer cells from growing. The goal of the study is to see if combining olutasidenib with the usual treatment can help patients get better or go into remission more often.

This trial is for adults aged 18 to 74 who have higher-risk MDS with the IDH1 mutation. If you join, you will receive the combination treatment and be closely monitored by doctors to see how well it works and to check for any side effects. The study is not yet open for new patients, but when it starts, it will include both men and women who meet the eligibility requirements. This trial offers a chance to try a new treatment that might improve outcomes for people with this specific type of blood disorder.

Gender

ALL

Eligibility criteria